Cell Therapy News/Articles, page-11596

Thanks @DocMcstuffins - I'll make sure I'll pass it onto SI when I talk to him next

You really don't think these sort of discussions have been had at the MSB headquarters?

It's a matter of priority and the priority atm is Rem-L for both GVHD and C19 ARDS, as they are based on the same product Rem-L.
Their paths cross and advancing one indication would also advance the other i.e. OTAT meeting is about Rem-L

SI has always expected 3 tiers approach to C19 - Vaccines, Antibodies and treatments; in a funnel volume based solution.
Vaccines do their job, but in the end - there's plenty of people still needing the final treatment when they end up in ICU and have C19 ARDS issues - the sooner we get Rem-L out there for these patients the better.

I'm astonished as a practicing doctor who have been working many shifts and see the devastating affect on C19 patients; that you wouldn't push for prioritising C19 ARDS treatment

In any case, I'm keen to see Mesoblast progress in any of the 4 shots at goal - as they are all unmet medical treatments - that will only serve patients better